Pacira Q1 revenue beats estimates, co raises 2026 outlook

Overview

• U.S. pain therapy maker's Q1 revenue up 5%, beating analyst expectations

• Adjusted EPS for Q1 beat consensus; adjusted net income and EBITDA missed estimates

• Company repurchased 2.2 mln shares for $50 mln in Q1

Outlook

• Pacira reiterates 2026 total revenue guidance of $745 mln to $770 mln

• Company expects 2026 EXPAREL net product sales of $600 mln to $620 mln

• Pacira anticipates key clinical trial readouts for ZILRETTA and PCRX-201 later in 2026

Result Drivers

• EXAREL VOLUME GROWTH - Co said EXPAREL sales rose on 7% volume growth, though offset by vial mix shifts, discounting from new GPO partnership, and returns tied to winter storm

• PORTFOLIO EXPANSION - Co attributed revenue growth to increased sales across EXPAREL, ZILRETTA, and iovera°, supported by expanding market access and adoption

• REAL-WORLD EVIDENCE - Co highlighted real-world studies showing EXPAREL use linked to lower healthcare costs and reduced opioid use in orthopedic procedures

Company press release: ID:nGNX30VMZb

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Pacira Biosciences Inc is $27.00, about 7.4% above its April 29 closing price of $25.14

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.